Clinical Trial

Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
A Study of Metabolically Armed EGFRvII CAR-T Cells Therapy for Patients With Recurrent Glioblastoma
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07244666
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Leman Biotech Co., Ltd.
Conditions Glioblastoma (GBM)
Enrollment 36 participants
Start Date 2025-11-15
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-24